Fecal Microbiota Transplantation: A Practical Update for the Infectious Disease Specialist
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Fecal microbiota transplantation (FMT) has been shown to be a superior therapeutic modality for the treatment of recurrent Clostridium difficile infection (RCDI). Recently the US Food and Drug Administration (FDA) determined that human stool should be classified as a biological agent and its use should be regulated to ensure patient safety. Consequently, the FDA determined that prescribers of FMT must possess an approved investigational new drug (IND) permit to administer FMT for the purpose of conducting research or treating any gastrointestinal condition other than RCDI. Although an IND is not required for use of FMT to treat RCDI, an IND is strongly encouraged and may ultimately be required. This article provides step-by-step guidance to infectious disease specialists on how to navigate the regulatory requirements and successfully obtain an IND before they can begin to use FMT as part of their clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent abstract reporting a survey of physicians showed that 40% were not willing to try FMT, pending further demonstration of its efficacy, safety and perceived patient acceptance.116”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [116]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 2×
“Most recently, an open-label, randomized, controlled trial directly comparing FMT with two different antibiotic regimens clearly demonstrated the superiority of FMT in patients with recurrent CDI” [7].”
BackgroundResultTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 2×
“Details regarding donor selection, screening, sample preparation, and administration details have been published previously and are not reviewed here [9, 11].”
BackgroundSelf-citation(1958) · PubMed · Cited by 978
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731 · cited 2×
“case series [9, 12] in patients with recurrent CDI resulting in superior cure rates compared to previously reported cure rates with standard therapy.”
BackgroundResultGerding, D. N. (1986) · Archives of Internal Medicine · doi:10.1001/archinte.1986.00360130117016 · Cited by 370
Miller, B. A., Chen, L. F., Sexton, D. J., & Anderson, D. J. (2011) · Infection Control & Hospital Epidemiology · doi:10.1086/659156 · Cited by 350 · cited 5×
“The website will contain online links to FDA forms 1571, 1572, and 3674; FMT protocol; and informed consent templates as well as a geographical map of FMT provider sites with contact information throughout the United States and Canada.”
BackgroundInfluentialEconomic healthcare costs of Clostridium difficile infection: a systematic review
Ghantoji, S. S., Sail, K., Lairson, D. R., DuPont, H. L., & Garey, K. W. (2010) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.10.016 · Cited by 288 · cited 1×
“associated deaths [2, 3] and annual costs exceeding $1 billion [4].”
BackgroundFecal bacteriotherapy for recurrent Clostridium difficile infection
Bakken, J. S. (2009) · Anaerobe · doi:10.1016/j.anaerobe.2009.09.007 · Cited by 218 · cited 4×
“Details regarding donor selection, screening, sample preparation, and administration details have been published previously and are not reviewed here [9, 11].”
BackgroundMethodResultInfluentialSelf-citationSchwartz, M., Gluck, M., & Koon, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.164 · Cited by 162 · cited 1×
“with FMT, including those not yet reported (eg, intestinal perforation, sepsis, transmission of an infectious agent from the donor stool [13]).”
BackgroundRubin, T. A., Gessert, C. E., Aas, J., & Bakken, J. (2012) · Anaerobe · doi:10.1016/j.anaerobe.2012.11.004 · Cited by 142 · cited 1×
“excess of 90%, with a negligible significant adverse event rate, regardless of route [10].”
BackgroundSelf-citation
Research works printed but not linked: 4
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
- Eiseman, 1958, Surgery, 44, 854
- 2012, 19, 22
- 2013, The American journal of gastroenterology, 108, 1367
Cited by
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Self-citationFecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O. G., Beaulieu, D. B., & Acra, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub2 · Cited by 164
“The short and long term safety of FMT in patients with IBD is not well established (Cammarota 2017; Kelly 2015; Moore 2014).”
BackgroundMethodInfluentialEffects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways
Chen, J., Zhao, K.-N., & Vitetta, L. (2019) · Nutrients · doi:10.3390/nu11051026 · Cited by 198
Fischer, M., Sipe, B., Cheng, Y.-W., Phelps, E., Rogers, N., Sagi, S., Bohm, M., Xu, H., & Kassam, Z. (2017) · Gut Microbes · doi:10.1080/19490976.2016.1273998 · Cited by 192
“The adoption of FMT by clinicians was hampered by logistics of preparation and complexity as well as cost of donor screening.(57) Universal stool banks emerged to ensure universal access to FMT and enable clinicians to treat CDI patients both effectively and safely.”
BackgroundHow to: establish and run a stool bank
Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J. F. M. L., Bauer, M. P., van Nood, E., Dijkgraaf, M. G. W., Mulder, C. J. J., Vandenbroucke-Grauls, C. M. J. E., Verspaget, H. W., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.015 · Cited by 168
Microbiome and PCOS: State-of-Art and Future Aspects
Giampaolino, P., Foreste, V., Di Filippo, C., Gallo, A., Mercorio, A., Serafino, P., Improda, F. P., Verrazzo, P., Zara, G., Buonfantino, C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042048 · Cited by 163
“However, to date, there are no clinical reports on the use of FMT to treat PCOS except murine models; prospective data obtained from laboratory researches should encourage further studies on humans [89].”
BackgroundFecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O., Borromeo Beaulieu, D. M., & Acra, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774 · Cited by 158
Hirsch, B. E., Saraiya, N., Poeth, K., Schwartz, R. M., Epstein, M. E., & Honig, G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0930-z · Cited by 150
“Additional strategies include oral vancomycin with an extended taper; rifaximin; intravenous tigecycline; toxin binding resins, monoclonal antibodies and various FMT modalities [29,42,45,59].”
BackgroundMethodWang, Z.-K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14805 · Cited by 133
Caldeira, L. D. F., Borba, H. H. L., Tonin, F. S., Wiens, A., Fernández-Llimós, F., & Pontarolo, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238910 · Cited by 118
“Since FMT is currently being considered as an experimental treatment for IBD [9], it is highly relevant to critically analyze the available evidence regarding this strategy, to guide clinicians.”
BackgroundFecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Pandit, N. G., Zaman, M., Minkoff, N. Z., Tanner‐Smith, E. E., Gomez-Duarte, O. G., Acra, S. A., & Nicholson, M. R. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub3 · Cited by 143
Jayasinghe, T. N., Chiavaroli, V., Holland, D. J., Cutfield, W. S., & O'Sullivan, J. M. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00015 · Cited by 77
Woodworth, M. H., Neish, E., Miller, N. S., Dhere, T., Burd, E. M., Carpentieri, C., Sitchenko, K. L., & Kraft, C. S. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02327-16 · Cited by 80
“Center for Biologics Evaluation and Research within the FDA classified human feces as a biologic agent and drug (15).”
BackgroundTempered Enthusiasm for Fecal Transplant
Solari, P. R., Fairchild, P. G., Noa, L. J., & Wallace, M. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu278 · Cited by 72
“(CDI) is based on reported efficacy and safety [1, 2].”
BackgroundU.S. Regulatory Considerations for Development of Live Biotherapeutic Products as Drugs
Dreher‐Lesnick, S. M., Stibitz, S., & Carlson, P. E. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0017-2017 · Cited by 85
“Other publications offer insights for investigators and clinicians for preparing the IND package itself, including examples of what to include for each section of the IND (11, 12).”
BackgroundVemuri, R. C., Gundamaraju, R., Shinde, T., & Eri, R. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0115 · Cited by 66
Lagier, J., Delord, M., Million, M., Parola, P., Stein, A., Brouqui, P., & Raoult, D. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2394-x · Cited by 66
Geng, S.-T., Zhang, Z., Wang, Y.-X., Lu, D., Yu, J., Zhang, J., Kuang, Y., & Wang, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.594820 · Cited by 64
Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease
Pavel, F. M., Vesa, C. M., Gheorghe, G., Diaconu, C. C., Stoicescu, M., Munteanu, M. A., Babeş, E. E., Ţiţ, D. M., Toma, M. M., & BUNGAU, S. G. (2021) · Diagnostics · doi:10.3390/diagnostics11061090 · Cited by 72
Fecal microbiota transplant – a new frontier in inflammatory bowel disease
Sunkara, T., Rawla, P., Ofosu, A., & Gaduputi, V. V. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s176190 · Cited by 72
“24”
Goldenberg, S. D., Batra, R., Beales, I., Digby-Bell, J. L., Irving, P. M., Kellingray, L., Narbad, A., & Franslem-Elumogo, N. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0189-y · Cited by 56
The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop?
Ser, H., Letchumanan, V., Goh, B. H., Wong, S. H., & Lee, L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.519836 · Cited by 63
Obesity and the gut microbiome: pathophysiological aspects
Bradlow, H. L. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0063 · Cited by 52
Fecal transplant policy and legislation
Vyas, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.6 · Cited by 51
The use of fecal microbiota transplant in sepsis
Keskey, R. C., Cone, J., DeFazio, J. R., & Alverdy, J. C. (2020) · Translational research · doi:10.1016/j.trsl.2020.07.002 · Cited by 54
Kelly, B. J., & Tebas, P. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.002 · Cited by 54
“Reviews provide valuable insight into CDI pathogenesis,7,15,46 setting up a frozen stool bank,47,48 FMT administration methods,49,50 and the details of FDA oversight of FMT.51,52 Here we review current FMT clinical practice, paying particular attention to issues relevant to FMT administration for patients who are hosp…”
BackgroundInfluentialTherapeutic manipulation of the microbiota: past, present, and considerations for the future
Young, V. B. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.001 · Cited by 54
Evolution of fecal microbiota transplantation in methodology and ethical issues
Zhang, F., Zhang, T., Zhu, H., & Borody, T. J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.004 · Cited by 48
Bakken, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu429 · Cited by 48
Self-citationGut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review
He, S., Lin, F., Hu, X., & Pan, P. (2023) · Nutrients · doi:10.3390/nu15224734 · Cited by 36
“Moreover, FMT may act against antibiotic-resistant CDI [17,59] and contribute to recovery from immunotherapy for colitis and the eradication of colonized antibiotic-resistant bacteria in patients with hematological malignancies [18,60].”
BackgroundMetabolic networks of the human gut microbiota
Selber‐Hnatiw, S., Sultana, T., Tse, W., Abdollahi, N., Abdullah, S., Rahbani, J. A., Alazar, D., Alrumhein, N. J., Aprikian, S., Arshad, R., et al. (2019) · Microbiology · doi:10.1099/mic.0.000853 · Cited by 41
Control of Clostridium difficile Infection by Defined Microbial Communities
Collins, J., & Auchtung, J. M. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0009-2016 · Cited by 44
“More comprehensive evaluations of FMT, including guides for clinicians on how to implement FMT, have been recently published (129, 130).”
Wang, Y., Hunt, A., Danziger, L. H., & Drwiega, E. N. (2024) · Antibiotics · doi:10.3390/antibiotics13050436 · Cited by 32
Thanush, D., Basavaraj, H. C., & Gowrav, M. P. (2023) · Advanced Gut & Microbiome Research · doi:10.1155/2023/6657515 · Cited by 40
Faecal microbiota transplantation: from practice to legislation before considering industrialization
Lagier, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12795 · Cited by 34
“Since then, alternative methods using colonoscopy, duodenal tubes or nasogastric tubes have been established [28,31].”
BackgroundMethodScheeler, A. (2019) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110519897729 · Cited by 28
Tang, L., Feng, W., Cheng, J.-J., & Gong, Y.-N. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03599-7 · Cited by 29
Azimirad, M., Jo, Y., Kim, M.-S., Jeong, M., Shahrokh, S., Aghdaei, H. A., Zali, M. R., Lee, S., Yadegar, A., & Shin, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s338212 · Cited by 23
“Clinical Diagnosis The criteria for receiving FMT were 1) at least three or more documented episodes of mild-to-moderate CDI, or at least two episodes of severe CDI requiring hospitalization and 2) failure of a 6- to 8-week course of therapy with tapered vancomycin.(14,17,18) Clinical, endoscopic, and histopathologic…”
MethodHoffman, P. S., Bruce, A. M., Olekhnovich, I. N., Warren, C. A., Burgess, S. L., Hontecillas, R., Viladomiu, M., Bassaganya-Riera, J., Guerrant, R. L., & Macdonald, T. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03112-14 · Cited by 20
Intervention strategies for microbial therapeutics in cancer immunotherapy
Gopalakrishnan, V., Weiner, B. J., Ford, C. B., Sellman, B. R., Hammond, S. A., Freeman, D. J., Dennis, P. A., Soria, J., Wortman, J. R., & Henn, M. R. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.05.001 · Cited by 22
Azimirad, M., Yadegar, A., Gholami, F., Shahrokh, S., Aghdaei, H. A., Ianiro, G., Suzuki, H., Cammarota, G., & Zali, M. R. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s265520 · Cited by 20
Fecal microbiota transplant for Clostridium difficile infection in older adults
Tauxe, W. M., Haydek, J. P., Rebolledo, P. A., Neish, E., Newman, K. L., Ward, A., Dhere, T., & Kraft, C. S. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15622600 · Cited by 19
Interaction Between Altered Gut Microbiota and Sepsis: A Hypothesis or an Authentic Fact?
Nabizadeh, E., Sadeghi, J., Rezaee, M. A., Hasani, A., Kafil, H. S., Ghotaslou, A., Kadkhoda, H., & Ghotaslou, R. (2022) · Journal of Intensive Care Medicine · doi:10.1177/08850666221102796 · Cited by 17
“It is believed that by doing this action, the colonization of pathogens is prevented by modulating the immune system, also the host metabolism is improved.(85) The use of this method dates back to centuries ago when it was used to treat food poisoning and dysentery associated with intestinal disorders.”
Fecal microbiota transplantation in treating C lostridium difficile infection
Brown, W. R. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12160 · Cited by 19
Therapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
Microbiology and Ecology Are Vitally Important to Premedical Curricula
Smith, V. H., Rubinstein, R., Park, S., Kelly, L., & Klepac‐Ceraj, V. (2015) · Evolution Medicine and Public Health · doi:10.1093/emph/eov014 · Cited by 15
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 10
Management of candidemia in patients withClostridium difficileinfection
Falcone, M., Venditti, M., Sanguinetti, M., & Posteraro, B. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1197118 · Cited by 8
Fever in Acute and Critical Care
Munro, N. (2014) · AACN Advanced Critical Care · doi:10.1097/nci.0000000000000041 · Cited by 11
Feces transplantation for recurrentClostridium difficileinfection: US experience and recommendations
Bakken, J. (2015) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v26.27657 · Cited by 8
“The practice of administering FMT was unregulated in the United States until February 2013, when the Federal Drug Administration (FDA) classified human stool as a biological drug and imposed restrictions on prescribers of FMT by requiring all providers of FMT to hold an approved new investigational drug (IND) permit (…”
BackgroundSelf-citationClostridium difficile infection: current, forgotten and emerging treatment options
Drekonja, D. M. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.36 · Cited by 5
Kang, S. H., Gweon, T., Hwang, H., & Baeg, M. K. (2022) · Clinical Endoscopy · doi:10.5946/ce.2021.199 · Cited by 4
“Recently, the indications for FMT have been expanded to include severe, complicated CDI that is refractory to medical treatment within 48 hours.(5) FMT has favorable efficacy in the treatment of fulminant CDI.”
BackgroundTHE POWER OF POOP: FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIUM DIFFICILE INFECTION.
Edmond, M. B. (2016) · PubMed Central · Cited by 5
United States Regulatory Considerations for Development of Live Biotherapeutic Products as Drugs
Dreher‐Lesnick, S. M., Stibitz, S., & Carlson, P. E. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch18 · Cited by 4
Diarrea asociada a Clostridium difficile en el anciano: nuevas perspectivas
Pareja‐Sierra, T. (2014) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2014.02.006 · Cited by 2
Pediatric Fecal Microbiota Transplantation
Mir, S. A. V., Kellermayer, R., & Gulati, A. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0049-5 · Cited by 2
Quels traitements innovants pour gagner la bataille des bactéries multi-résistantes ?
Tattevin, P., Lorleac’h, A., & Revest, M. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31313-5 · Cited by 3
Cross-talking between polycystic ovarian syndrome and gut microbiome: a comprehensive review
Choudhury, S. R., Koner, S., & Dey, R. (2026) · Middle East Fertility Society Journal · doi:10.1186/s43043-026-00304-6 · Cited by 1
“They then treat with probiotics (3 billion CFU per day by mouth Transfers microbiota from healthy donors to restore intestinal homeostasis and hormonal/ metabolic con-trol [108].”
InfluentialFecal microbiota transplantation: why, who, how?
Yalçın, S. S., & Kanatlı, M. Ç. (2015) · Pamukkale Medical Journal · doi:10.5505/ptd.2015.22448 · Cited by 2
“152 düzelme hızı bildiren çalışmaların yanı sıra donör ve alıcı arasındaki yakınlığın CDE sağaltımını değiştirmediğini gösteren çalışmalar da vardır [22,29,31,32,34].”
Alberca, G. G. F., Sato, M. N., & Alberca, R. W. (2019) · General Internal Medicine and Clinical Innovations · doi:10.15761/gimci.1000179 · Cited by 1
Lteif, L. (2017) · Europe PMC (PubMed Central) · Cited by 1
GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet
(2015) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v26.28480
Phenolic Glycolipid-I Does Not Cross-react With Visceral Leishmaniasis Sera in a Brazilian Subset
de Moura, R. S., Bührer-Sékula, S., Jerônimo, S. M. B., & Stefani, M. M. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu277
Fäkaler Mikrobiomtransfer – Schritt für Schritt
Wagner, M., & Rauschek, L. (2018) · Gastroenterologie up2date · doi:10.1055/a-0601-9519
“In diesem Fall sollte vor dem FMT eine Perforation mit einem bildgebenden Verfahren ausgeschlossen werden [3].”
Savelkoul, E. H. J., Pathmakanthan, S., Hawkey, P. M., & Iqbal, T. H. (2018) · Gastrointestinal Nursing · doi:10.12968/gasn.2018.16.9.43 · Cited by 1
Utilization of Faecal Microbiota in Humans and Animals
kwang-keun, C., Kim, S.-H., Park, S.-Y., Lee, J. M., & Jo, S.-Y. (2020) · Journal of Agriculture & Life Science · doi:10.14397/jals.2020.54.1.1
Fenollar, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00039-3
Control of Clostridium difficile Infection by Defined Microbial Communities
Collins, J., & Auchtung, J. M. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch11 · Cited by 1
Quigley, E. M. M. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732918568.793569656
Metadata
- Authors
- Moore, T., Rodriguez, A., & Bakken, J. S.
- Affiliations
- Infectious Diseases Society of America (US)
- St. Luke's Hospital (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-23
- Volume
- 58
- Issue
- 4
- Pages
- 541-545
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2111426729
- Cited by
- 69
- References
- 13
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 8 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 9 · 2014: 13
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American College of Gastroenterology
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, FDA regulation, regulatory requirements, patient safety
- MeSH terms
- Biological Therapy, Feces, Gastrointestinal Diseases, Humans, United States, Drugs, Investigational, Investigational New Drug Application
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.